Budget impact analysis of aztreonam-avibactam for metallo-β-lactamase carbapenem-resistant enterobacterales infections in China
Infection · 2026-08 · 54 (4) · 1839-1848
DOI: 10.1007/s15010-026-02801-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection, online erschienen am 04.05.2026. Verfasst von Junling Weng und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Fudan University, 130 Dongan Rd, Xuhui, 200032, Shanghai, China. Hauptthemen laut MEDLINE: Aztreonam, Azabicyclo Compounds, Anti-Bacterial Agents, Enterobacteriaceae Infections. Die Arbeit nennt 48 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To evaluate the budget impact on the China's basic medical insurance fund (BMIF) following the inclusion of aztreonam-avibactam (ATM-AVI) for metallo-β-lactamase carbapenem-resistant enterobacterales (MBL-CRE) infections in the National Reimbursement Drug List (NRDL). METHODS: A budget impact model was developed with a 2-year time horizon (2026-2027) from the perspective of China's basic medical insurance. The analysis included drug acquisition costs and other direct medical costs. Relevant data were collected from published literature, and supplemented through expert consultation. The study compared costs under two scenarios with and without ATM-AVI reimbursement to estimate its impact on BMIF. One way sensitivity analyses were conducted to identify key parameters influencing the results. RESULTS: After the inclusion of ATM-AVI in the NRDL, the BMIF was projected to save 152,156,598 Chinese yuan (21,310,448 United States dollar) and 210,914,875 Chinese yuan (29,539,898 United States dollar) in 2026 and 2027, respectively. Following reimbursement, ATM-AVI was expected to yield 291 and 342 additional cured patients, 804 and 888 fewer deaths, 11,256 and 13,031 fewer intensive care unit days, and 11,336 and 13,071 fewer total hospitalization days in 2026 and 2027, respectively. Across all parameter variations, ATM-AVI remained cost-saving to BMIF. CONCLUSION: In China, timely reimbursement of innovative antibiotics can simultaneously improve patient outcomes and reduce medical insurance fund expenditure, underscoring the value of value-based reimbursement policies in promoting access to effective therapies while supporting the sustainability of the health insurance system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Public Health, Fudan University, 130 Dongan Rd, Xuhui, 200032, Shanghai, China.
- National Health Commission Key Laboratory of Health Technology Assessment (Fudan University), 200032, Shanghai, China.
- Center for Global Health, School of Public Health, Nanjing Medical University, 211166, Nanjing, Jiangsu, China.
- School of Public Health, Fudan University, 130 Dongan Rd, Xuhui, 200032, Shanghai, China. fd_yangyi@fudan.edu.cn.
- National Health Commission Key Laboratory of Health Technology Assessment (Fudan University), 200032, Shanghai, China. fd_yangyi@fudan.edu.cn.
- School of Public Health, Fudan University, 130 Dongan Rd, Xuhui, 200032, Shanghai, China. yychen@shmu.edu.cn.
Zitieren
APA
Weng, J., Zhang, K., Liu, Q., Xiao, D., Zhou, Z., Yang, Y., Li, X., & Chen, Y. (2026). Budget impact analysis of aztreonam-avibactam for metallo-β-lactamase carbapenem-resistant enterobacterales infections in China. Infection, 54(4), 1839-1848. https://doi.org/10.1007/s15010-026-02801-2
Vancouver
Weng J, Zhang K, Liu Q, Xiao D, Zhou Z, Yang Y, et al. Budget impact analysis of aztreonam-avibactam for metallo-β-lactamase carbapenem-resistant enterobacterales infections in China. Infection. 2026;54(4):1839-1848. doi:10.1007/s15010-026-02801-2
BibTeX
@article{Weng2026,
author = {Weng, Junling and Zhang, Kemiao and Liu, Qiang and Xiao, Dunming and Zhou, Zichun and Yang, Yi and Li, Xin and Chen, Yingyao},
title = {Budget impact analysis of aztreonam-avibactam for metallo-β-lactamase carbapenem-resistant enterobacterales infections in China},
journal = {Infection},
year = {2026},
volume = {54},
number = {4},
pages = {1839--1848},
doi = {10.1007/s15010-026-02801-2}
}
EUVIMED